Gene:
PIK3CB
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  None
Alternate Symbols:  None
PharmGKB Accession Id: PA33309

Details

Cytogenetic Location: chr3 : q22.3 - q22.3
GP mRNA Boundary: chr3 : 138374231 - 138478185
GP Gene Boundary: chr3 : 138371231 - 138488185
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Anti-diabetic Drug Potassium Channel Inhibitors Pathway, Pharmacodynamics
    Representation of anti-diabetic drugs repaglinide, nateglinide and sulfonylurea effects on insulin secretion in pancreatic cells.
  1. EGFR Inhibitor Pathway, Pharmacodynamics
    Model non-tissue specific cancer cell displaying genes that may be involved in the treatment using epidermal growth factor receptor specific tyrosine kinase inhibitors or monoclonal antibodies.
  1. Sorafenib Pharmacodynamics
    Mechanism of action of sorafenib

External Pathways

Links to non-PharmGKB pathways.

  1. LPA receptor mediated events - (Pathway Interaction Database NCI-Nature Curated)

Curated Information ?

Evidence Gene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
AKT1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
FLT1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
FLT4
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
KDR
No related diseases are available

Publications related to PIK3CB: 2

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Structural comparisons of class I phosphoinositide 3-kinases. Nature reviews. Cancer. 2008. Amzel L Mario, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Antagonism of rat beta-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways. The Journal of biological chemistry. 2003. MacDonald Patrick E, et al. PubMed

LinkOuts

Entrez Gene:
5291
OMIM:
602925
UCSC Genome Browser:
NM_006219
RefSeq RNA:
NM_006219
RefSeq Protein:
NP_006210
RefSeq DNA:
AC_000046
AC_000135
NC_000003
NT_005612
NW_001838884
NW_921807
UniProtKB:
PK3CB_HUMAN (P42338)
Ensembl:
ENSG00000051382
GenAtlas:
PIK3CB
GeneCard:
PIK3CB
MutDB:
PIK3CB
ALFRED:
LO035697E
HuGE:
PIK3CB
Comparative Toxicogenomics Database:
5291
ModBase:
P42338
HumanCyc Gene:
HS00644
HGNC:
8976

Common Searches